Carlsmed (NASDAQ:CARL) Price Target Raised to $22.00

Carlsmed (NASDAQ:CARL – Free Report) had its price target hoisted by Needham & Company LLC from $17.00 to $22.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. BTIG Research raised their target price on shares of Carlsmed from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Truist Financial lifted their price target on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a research report on Wednesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

Check Out Our Latest Analysis on CARL

Carlsmed Price Performance

Shares of CARL opened at $17.12 on Wednesday. Carlsmed has a 1-year low of $8.50 and a 1-year high of $19.15. The company’s fifty day simple moving average is $14.97 and its 200 day simple moving average is $12.58. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.66 and a current ratio of 5.79.

Carlsmed (NASDAQ:CARL – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.08. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. The firm had revenue of $21.55 million for the quarter. As a group, analysts expect that Carlsmed will post -1.53 EPS for the current fiscal year.

Institutional Trading of Carlsmed

Several institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG bought a new position in Carlsmed during the 2nd quarter worth $106,000. Bank of America Corp DE bought a new stake in shares of Carlsmed in the second quarter valued at about $108,000. Alpine Woods Capital Investors LLC bought a new stake in shares of Carlsmed in the second quarter valued at about $161,000. Bank of New York Mellon Corp acquired a new position in shares of Carlsmed in the second quarter valued at about $181,000. Finally, Zevenbergen Capital Investments LLC grew its stake in shares of Carlsmed by 50.4% in the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after acquiring an additional 6,000 shares in the last quarter.

Carlsmed Company Profile

(Get Free Report)

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.

See Also

Analyst Recommendations for Carlsmed (NASDAQ:CARL)

Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.